开云app官网登录入口网页版-官方正版

#BAT#

26篇内容 | 1376人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1930322, encodeId=f57819303222b, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, objectTitle=JGH: 依洛昔巴特(Elobixibat)对慢性便秘患者血清和粪便胆汁酸水平及便秘症状的影响, objectType=article, longId=728071, objectId=9b82e28071be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b82e28071be, replyNumber=0, likeNumber=81, createdTime=2022-09-05, rootId=0, userName=日月, userId=4a4d285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b82e28071be, moduleTitle=JGH: 依洛昔巴特(Elobixibat)对慢性便秘患者血清和粪便胆汁酸水平及便秘症状的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9b82e28071be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1930321, encodeId=f5f6193032125, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, objectTitle=JGH: 依洛西巴特(Elobixibat)对慢性便秘患者血清和粪便胆汁酸水平及便秘症状的影响, objectType=article, longId=299241, objectId=7e7c29924183, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e7c29924183, replyNumber=0, likeNumber=54, createdTime=2022-09-04, rootId=0, userName=日月, userId=4a4d285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e7c29924183, moduleTitle=JGH: 依洛西巴特(Elobixibat)对慢性便秘患者血清和粪便胆汁酸水平及便秘症状的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7e7c29924183)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1930319, encodeId=b56d1930319fa, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, objectTitle=Aliment Pharmacol Ther：elobixibat通过影响分泌性胆汁酸来改善慢性便秘, objectType=article, longId=211217, objectId=e10121121e32, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e10121121e32, replyNumber=0, likeNumber=67, createdTime=2022-04-07, rootId=0, userName=日月, userId=4a4d285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e10121121e32, moduleTitle=Aliment Pharmacol Ther：elobixibat通过影响分泌性胆汁酸来改善慢性便秘, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e10121121e32)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1930314, encodeId=2d471930314ac, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, objectTitle=NAT MED：反义寡核苷酸治疗CLN3 Batten病, objectType=article, longId=198337, objectId=115919833e67, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=115919833e67, replyNumber=0, likeNumber=50, createdTime=2021-03-21, rootId=0, userName=日月, userId=4a4d285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=115919833e67, moduleTitle=NAT MED：反义寡核苷酸治疗CLN3 Batten病, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=115919833e67)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1930318, encodeId=932619303182c, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, objectTitle=J Clin Oncol：Abatacept协同刺激阻断可明显有效预防急性GVHD！, objectType=article, longId=206294, objectId=1ff32062949d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ff32062949d, replyNumber=0, likeNumber=79, createdTime=2021-06-15, rootId=0, userName=日月, userId=4a4d285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ff32062949d, moduleTitle=J Clin Oncol：Abatacept协同刺激阻断可明显有效预防急性GVHD！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1ff32062949d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1930320, encodeId=3aec1930320f4, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, objectTitle=Ann Neurol：vigabatrin预防性治疗可降低结节性硬化综合症患儿癫痫的发作风险和严重程度, objectType=article, longId=211226, objectId=31d02112268e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31d02112268e, replyNumber=0, likeNumber=78, createdTime=2021-08-13, rootId=0, userName=日月, userId=4a4d285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31d02112268e, moduleTitle=Ann Neurol：vigabatrin预防性治疗可降低结节性硬化综合症患儿癫痫的发作风险和严重程度, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=31d02112268e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1930317, encodeId=94b7193031e1c, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, objectTitle=Bio-Thera向欧洲药品管理局提交了Avastin生物仿制药BAT1706的营销授权申请（MAA）。, objectType=article, longId=203853, objectId=e1e7203853fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1e7203853fc, replyNumber=0, likeNumber=76, createdTime=2020-12-23, rootId=0, userName=日月, userId=4a4d285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1e7203853fc, moduleTitle=Bio-Thera向欧洲药品管理局提交了Avastin生物仿制药BAT1706的营销授权申请（MAA）。, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e1e7203853fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1930315, encodeId=2091193031553, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, objectTitle=Nat Mebat：胰岛细胞皮下移植获突破，新技术成功逆转1型糖尿病, objectType=article, longId=200845, objectId=58902008458f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58902008458f, replyNumber=0, likeNumber=0, createdTime=2021-08-06, rootId=0, userName=日月, userId=4a4d285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58902008458f, moduleTitle=Nat Mebat：胰岛细胞皮下移植获突破，新技术成功逆转1型糖尿病, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=58902008458f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1930316, encodeId=f0bb193031689, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, objectTitle=JACC Cardiovasc Interv：在治疗有症状的股骨膜病变时，Zilver PTX支架似乎并不优于Misago支架——BATTLE试验1年研究结果, objectType=article, longId=203336, objectId=cf2b203336a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf2b203336a3, replyNumber=0, likeNumber=61, createdTime=2021-04-16, rootId=0, userName=日月, userId=4a4d285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf2b203336a3, moduleTitle=JACC Cardiovasc Interv：在治疗有症状的股骨膜病变时，Zilver PTX支架似乎并不优于Misago支架——BATTLE试验1年研究结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=cf2b203336a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1930313, encodeId=aefa1930313f1, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, objectTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, objectType=article, longId=195490, objectId=a38e195490b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38e195490b9, replyNumber=0, likeNumber=63, createdTime=2020-12-12, rootId=0, userName=日月, userId=4a4d285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38e195490b9, moduleTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a38e195490b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1930310, encodeId=7b6219303107a, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, objectTitle=ASCO 2020年度胃肠道癌专题讨论会：LONSURF和Futibatinib（TAS-120）的全新数据, objectType=article, longId=186810, objectId=ee3118681049, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee3118681049, replyNumber=0, likeNumber=63, createdTime=2020-11-20, rootId=0, userName=日月, userId=4a4d285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee3118681049, moduleTitle=ASCO 2020年度胃肠道癌专题讨论会：LONSURF和Futibatinib（TAS-120）的全新数据, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ee3118681049)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1930309, encodeId=bb71193030977, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, objectTitle=106家大健康初创背后：BAT 和平安正在完成健康产业布局, objectType=article, longId=186248, objectId=17ab18624809, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17ab18624809, replyNumber=0, likeNumber=72, createdTime=2020-07-20, rootId=0, userName=日月, userId=4a4d285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17ab18624809, moduleTitle=106家大健康初创背后：BAT 和平安正在完成健康产业布局, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=17ab18624809)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1930311, encodeId=87de1930311bc, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, objectTitle=胆道闭锁治疗取得新进展：美国FDA已批准Odevixibat的IND申请, objectType=article, longId=186999, objectId=f95c18699928, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f95c18699928, replyNumber=0, likeNumber=65, createdTime=2020-05-24, rootId=0, userName=日月, userId=4a4d285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f95c18699928, moduleTitle=胆道闭锁治疗取得新进展：美国FDA已批准Odevixibat的IND申请, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f95c18699928)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1930312, encodeId=68ec193031239, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, objectTitle=BMC Gastroenterology： Elobixibat可以缓解血液透析患者的慢性便秘, objectType=article, longId=188236, objectId=a5ca188236cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5ca188236cd, replyNumber=0, likeNumber=57, createdTime=2020-09-15, rootId=0, userName=日月, userId=4a4d285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5ca188236cd, moduleTitle=BMC Gastroenterology： Elobixibat可以缓解血液透析患者的慢性便秘, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a5ca188236cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1930308, encodeId=4d771930308f0, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, objectTitle=互联网医疗烧钱成瘾，BAT谁才是“救火英雄”, objectType=article, longId=167158, objectId=547116e158b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=547116e158b7, replyNumber=0, likeNumber=56, createdTime=2019-10-05, rootId=0, userName=日月, userId=4a4d285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=547116e158b7, moduleTitle=互联网医疗烧钱成瘾，BAT谁才是“救火英雄”, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=547116e158b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1930307, encodeId=6962193030e47, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, objectTitle=由于定价过高，英国NICE拒绝了BioMarin的Batten疾病治疗药物, objectType=article, longId=160827, objectId=25b316082e05, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25b316082e05, replyNumber=0, likeNumber=72, createdTime=2019-04-20, rootId=0, userName=日月, userId=4a4d285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25b316082e05, moduleTitle=由于定价过高，英国NICE拒绝了BioMarin的Batten疾病治疗药物, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=25b316082e05)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1930306, encodeId=348119303068b, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, objectTitle=大看点丨医疗AI火出新高度 BAT与GPS争相布局, objectType=article, longId=146205, objectId=847714620552, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=847714620552, replyNumber=0, likeNumber=64, createdTime=2019-03-18, rootId=0, userName=日月, userId=4a4d285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=847714620552, moduleTitle=大看点丨医疗AI火出新高度 BAT与GPS争相布局, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=847714620552)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1930305, encodeId=8ba9193030570, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, objectTitle=医疗 AI 火出新高度，融资总额超219亿，BAT 与 GPS 争相布局, objectType=article, longId=142935, objectId=1b5d142935a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b5d142935a1, replyNumber=0, likeNumber=58, createdTime=2019-01-15, rootId=0, userName=日月, userId=4a4d285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b5d142935a1, moduleTitle=医疗 AI 火出新高度，融资总额超219亿，BAT 与 GPS 争相布局, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1b5d142935a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1930304, encodeId=de6b193030426, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, objectTitle=Lancet Gastroen Hepatol：Elobixibat治疗慢性便秘效果显著, objectType=article, longId=139103, objectId=fdd013910344, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdd013910344, replyNumber=0, likeNumber=88, createdTime=2018-12-29, rootId=0, userName=日月, userId=4a4d285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdd013910344, moduleTitle=Lancet Gastroen Hepatol：Elobixibat治疗慢性便秘效果显著, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fdd013910344)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1930303, encodeId=7f131930303c7, content=<a href='/topic/show?id=87b8322658' target=_blank style='color:#2F92EE;'>#BAT#</a>, objectTitle=BAT海外医疗投资谱　“生态帝国”显现, objectType=article, longId=134306, objectId=37e51343061e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37e51343061e, replyNumber=0, likeNumber=57, createdTime=2019-01-14, rootId=0, userName=日月, userId=4a4d285, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37e51343061e, moduleTitle=BAT海外医疗投资谱　“生态帝国”显现, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=37e51343061e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

BAT

2020-05-29

日月 (审核中...)

前往app查看评论内容

#BAT#

JGH: 依洛昔巴特(Elobixibat)对慢性便秘患者血清和粪便胆汁酸水平及便秘症状的影响

2022-09-05

日月 (审核中...)

前往app查看评论内容

#BAT#

JGH: 依洛西巴特(Elobixibat)对慢性便秘患者血清和粪便胆汁酸水平及便秘症状的影响

2022-09-04

日月 (审核中...)

前往app查看评论内容

#BAT#

Aliment Pharmacol Ther：elobixibat通过影响分泌性胆汁酸来改善慢性便秘

2022-04-07

日月 (审核中...)

前往app查看评论内容

#BAT#

NAT MED：反义寡核苷酸治疗CLN3 Batten病

2021-03-21

日月 (审核中...)

前往app查看评论内容

#BAT#

J Clin Oncol：Abatacept协同刺激阻断可明显有效预防急性GVHD！

2021-06-15

日月 (审核中...)

前往app查看评论内容

#BAT#

Ann Neurol：vigabatrin预防性治疗可降低结节性硬化综合症患儿癫痫的发作风险和严重程度

2021-08-13

日月 (审核中...)

前往app查看评论内容

#BAT#

Bio-Thera向欧洲药品管理局提交了Avastin生物仿制药BAT1706的营销授权申请（MAA）。

2020-12-23

日月 (审核中...)

前往app查看评论内容

#BAT#

Nat Mebat：胰岛细胞皮下移植获突破，新技术成功逆转1型糖尿病

2021-08-06

日月 (审核中...)

前往app查看评论内容

#BAT#

JACC Cardiovasc Interv：在治疗有症状的股骨膜病变时，Zilver PTX支架似乎并不优于Misago支架——BATTLE试验1年研究结果

2021-04-16

日月 (审核中...)

前往app查看评论内容

#BAT#

EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept

2020-12-12

日月 (审核中...)

前往app查看评论内容

#BAT#

ASCO 2020年度胃肠道癌专题讨论会：LONSURF和Futibatinib（TAS-120）的全新数据

2020-11-20

日月 (审核中...)

前往app查看评论内容

#BAT#

106家大健康初创背后：BAT 和平安正在完成健康产业布局

2020-07-20

日月 (审核中...)

前往app查看评论内容

#BAT#

胆道闭锁治疗取得新进展：美国FDA已批准Odevixibat的IND申请

2020-05-24

日月 (审核中...)

前往app查看评论内容

#BAT#

BMC Gastroenterology： Elobixibat可以缓解血液透析患者的慢性便秘

2020-09-15

日月 (审核中...)

前往app查看评论内容

#BAT#

互联网医疗烧钱成瘾，BAT谁才是“救火英雄”

2019-10-05

日月 (审核中...)

前往app查看评论内容

#BAT#

由于定价过高，英国NICE拒绝了BioMarin的Batten疾病治疗药物

2019-04-20

日月 (审核中...)

前往app查看评论内容

#BAT#

大看点丨医疗AI火出新高度 BAT与GPS争相布局

2019-03-18

日月 (审核中...)

前往app查看评论内容

#BAT#

医疗 AI 火出新高度，融资总额超219亿，BAT 与 GPS 争相布局

2019-01-15

日月 (审核中...)

前往app查看评论内容

#BAT#

Lancet Gastroen Hepatol：Elobixibat治疗慢性便秘效果显著

2018-12-29

日月 (审核中...)

前往app查看评论内容

#BAT#

BAT海外医疗投资谱　“生态帝国”显现

2019-01-14

科室
- - 订阅+
  - 更多科室
工具
服务